Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease

Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease

Objective: This study aims to investigate the clinical efficacy of Ganshuang granules combined with tenofovir, an antiviral drug, in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease.Methods: A total of 92 patients with chronic hepatitis B combined with non-alcoh...

Full description

Bibliographic Details
Main Authors:	Changtian Su, Qin Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Pharmacology
Subjects:	ganshuang granule chronic hepatitis B non-alcoholic fatty liver disease antiviral therapy clinical trial
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1032789/full

Similar Items

Research progress of the impact of nonalcoholic fatty liver disease on chronic hepatitis B infection
by: BENEDICK Jun Er Chin, et al.
Published: (2023-12-01)

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
by: David Sooik Kim, et al.
Published: (2019-09-01)

Integrative proteomics and metabolomics explore the effect and mechanism of Qiyin granules on improving nonalcoholic fatty liver disease
by: Xuehua Yan, et al.
Published: (2024-03-01)

Obesity and nonalcoholic fatty liver disease: current perspectives
by: Sarwar R, et al.
Published: (2018-09-01)

Features of nonalcoholic fatty liver disease pharmacotherapy in patients with overweight and obesity
by: K. V. Pivtorak
Published: (2017-08-01)

Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome
by: Ma Ai Thanda Han
Published: (2020-09-01)

Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis
by: Rasha AlShaalan, et al.
Published: (2015-01-01)

Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial
by: Yuanlong Sun, et al.
Published: (2022-06-01)

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
by: Yong Kyun Cho
Published: (2018-09-01)

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
by: Eileen Laurel Yoon, et al.
Published: (2023-04-01)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
by: Saba Sayari, et al.
Published: (2018-09-01)

Danshao Shugan Granule therapy for non-alcoholic fatty liver disease
by: Hui Wang, et al.
Published: (2022-08-01)

What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
by: Giovanni Tarantino, et al.
Published: (2024-02-01)

Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease
by: Misael Uribe, et al.
Published: (2008-01-01)

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
by: Cheng Han Ng, et al.
Published: (2022-07-01)

Hepatitis C and Nonalcoholic Steatohepatitis in the 21st Century: Impact on Liver Disease and Liver Transplantation
by: Sonia Samuel, et al.
Published: (2023-06-01)

The effect of moderate alcohol drinking in nonalcoholic fatty liver disease
by: Jong Hwa Choi, et al.
Published: (2020-10-01)

Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis
by: Jinwang Li, et al.
Published: (2021-12-01)

Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
by: Lili Liu, et al.
Published: (2023-01-01)

Nonalcoholic fatty liver disease: What do we know and what will we have to learn?
by: N I Volkova, et al.
Published: (2017-02-01)

Portal venous and hepatic artery hemodynamic variation in non-alcoholic fatty liver disease
by: Manal Sabry, et al.
Published: (2021-06-01)

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B
by: S. N. Batskikh, et al.
Published: (2020-09-01)

The Effect of Tenofovir Treatment on Renal Function in Chronic Hepatitis B Patients
by: Yusuf Kayar, et al.
Published: (2019-10-01)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023-02-01)

Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases
by: Ciniso Sylvester Shabangu, et al.
Published: (2020-05-01)

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
by: Ji-Won Park, et al.
Published: (2023-04-01)

Leptin in nonalcoholic fatty liver disease
by: Billur Canbakan, et al.
Published: (2008-07-01)

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Published: (2013-12-01)

Correlation between Nonalcoholic Fatty Liver Disease and Early Left Ventricular Diastolic Dysfunction
by: Fangyuan CONG, Qian XUE, Lihua DENG, Luying ZHU, Jingtong WANG
Published: (2022-09-01)

Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials
by: Ting-Rui Han, et al.
Published: (2023-01-01)

Novel Ultrasonographic Fatty Liver Indicator Can Predict Hepatitis in Children With Non-alcoholic Fatty Liver Disease
by: Hsien-Kuan Liu, et al.
Published: (2019-01-01)

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
by: Hyo Young Lee, et al.
Published: (2019-03-01)

Рrospects for the use of “dry” carbon dioxide baths in patients with chronic viral hepatitis c with concomitant non-alcoholic fatty liver disease (literature review and own research)
by: Anna Izha
Published: (2020-06-01)

Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease
by: Yiwen Zhang, et al.
Published: (2019-11-01)

Implications of comorbidities in nonalcoholic fatty liver disease
by: Sherlot Juan Song, et al.
Published: (2023-04-01)

Gut microbiota and nonalcoholic fatty liver disease
by: Boyeon Kim, et al.
Published: (2023-09-01)

Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
by: Dae Ho Lee
Published: (2020-06-01)

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
by: Karn Wijarnpreecha, et al.
Published: (2021-04-01)

Effect of tele-nursing in the improving of the ultrasound findings in patients with nonalcoholic fatty liver diseases: A Randomized Clinical Trial study
by: Fariba Ghodsbin, et al.
Published: (2018-11-01)

Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?
by: Julia A. Golubeva, et al.
Published: (2023-09-01)